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T e growing number of advances in human 
genomic research that are directly relevant 
to disease diagnosis, treatment, and pre-
vention coupled with the declining cost of 
genome sequencing has promoted the use 
of genomic technologies in routine clini-
cal care (1). Among the many challenges 
to widespread implementation of genomic 
medicine, what looms largest is the lack of 
evidence to demonstrate improved clinical 
or economic outcomes (2). Other needs in-
clude standardization and quality assurance 
of genomic data produced by clinical labo-
ratories, a clinical-informatics infrastruc-
ture for managing genomic information, 
education for health professionals and pa-
tients in using the information, and policies 
for data sharing that permit ongoing cap-
ture of generalizable clinical experiences in 
what has been termed “evidence-generating 
medicine” (3). A host of ongoing ef orts ex-
ist worldwide to establish national imple-
mentation strategies for genomic medicine 
(table S1) (4), but many such ef orts are be-
ing conducted in relative isolation. Sharing 
of strategies, data, and standards could min-
imize wasteful duplication and speed prog-
ress in identifying genomics-based inter-
ventions and translating them to the clinic.
To assess the current global state of the
art (2), the U.S. National Human Genome 
Research Institute and the U.S. National 
Academy of Medicine convened 90 leaders 
in genomic medicine from the United States 
and 25 other countries on f ve continents 
for a Global Leaders in Genomic Medicine
symposium in 2014 (table S1). Although the 
organizers attempted to identify and invite 
every nation working on the implementa-
tion of genomic medicine, participation was 
somewhat restricted by the lack of system-
atic information on such ef orts and limited 
travel funding [see full list of participating 
countries at www.genome.gov/27555775]. 
Here we summarize ef orts described by 
the participants, with an emphasis on (i) 
regions with singular capabilities because of 
the structures of their health care systems, 
cultural or political readiness for imple-
mentation, or unusual disease burdens or 
risk-allele frequencies; (ii) the current state 
of implementation in the various countries 
and capabilities desired over the next 3 to 5 
years; and (iii) opportunities for collabora-
tion to promote the responsible implemen-
tation of genomic medicine.
INTERNATIONAL LANDSCAPE
Early ef orts at genomic-medicine collabo-
rations include the European Association 
for Predictive, Preventive, and Personalised 
Medicine (EPMA), the European Com-
mission’s EuroBioForum and observatory, 
and the Genomic Medicine Alliance (table 
S1) (5), which have spearheaded promising 
projects such as the application of genome 
sequencing in pharmacogenomics and the 
development of online pharmacogenomic 
resources. Related ef orts include the Inter-
national Rare Disease Research Consortium 
(IRDiRC), which is developing new diag-
nostic strategies and therapies for rare dis-
eases; the Global Alliance for Genomics and 
Health (GA4GH), which promotes respon-
sible sharing of genomic data for research 
(6); and EuroGentest (table S1), which is 
draf ing professional guidelines for diagnos-
tic DNA sequencing.
In an informal poll of participants prior 
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Around the world, innovative genomic-medicine programs capitalize on singular capabili-
ties arising from local health care systems, cultural or political milieus, and unusual se-
lected risk alleles or disease burdens. Such individual ef orts might benef t from the shar-
ing of approaches and lessons learned in other locales. The U.S. National Human Genome 
Research Institute and the National Academy of Medicine recently brought together 25 of 
these groups to compare projects, to examine the current state of implementation and de-
sired near-term capabilities, and to identify opportunities for collaboration that promote 
the responsible practice of genomic medicine. Ef orts to coalesce these groups around 
concrete but compelling signature projects should accelerate the responsible implementa-
tion of genomic medicine in ef orts to improve clinical care worldwide.
Teamwork: Clearing of hurdles to the clinical translation of genomic medicine demands a 
unif ed focus. CR
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to the symposium, nearly all sites reported 
some genomic medicine capabilities, such 
as using genotyping or genome or exome 
sequencing for disease prediction, diag-
nosis, prevention, and treatment as well 
as family counseling (Table 1). More than 
70% of respondents reported the availabil-
ity, in specialized centers only, of clinical 
genomic sequencing resources for targeted 
cancer treatment, rare disease diagnosis, 
and microbial pathogen identif cation, 
while ~10% reported these capabilities to 
be widely available. Conversely, more than 
half reported the lack of any capabilities 
for newborn genomic sequencing or RNA, 
metabolomics, or proteomic prof ling. Over 
the next 3 to 5 years, participants hope to 
see substantial gains in the availability of 
clinical genomic resources, particularly for 
pharmacogenomics, pathogen identif ca-
tion, genetic counseling, electronic medical 
records (EMRs), and clinical-decision sup-
port. Several other technologies, including 
newborn sequencing, rare disease diag-
nosis, and RNA prof ling, were projected 
to become available, within 3 to 5 years, 
in specialized centers where no capabil-
ity currently exists.   e barriers to global 
implementation of genomic medicine 
worldwide (Table 2) are similar to those 
identif ed in a 2012 survey that examined 
U.S. genomic medicine–implementation 
ef orts (2), reinforcing the notion that the 
global genomic-medicine community 
shares important challenges and goals. 
  e most common implementation ef-
forts involve cancer genomics, large-scale 
exome or whole-genome sequencing, and 
pharmacogenomics, while several current 
projects focus on particular geographi-
cal priorities (table S2). National ef orts to 
build infrastructures for genome sequenc-
ing and other genomic and information 
technologies are under way in nearly all 
countries represented at the symposium. 
Table 1. Haves and have nots. Selected current and desired genomic medicine capabilities across participating countries and regions (number 
surveyed = 25). 
 Today (%) Desired in 3 to 5 years (%) 
Capability Not at all Specialized 
centers 
Widely available Not at all Specialized 
centers 
Widely available 
Pharmacogenomics 23 66 11 17 29 56 
Germline sequencing 23 66 11 11 72 17 
Tumor sequencing 17 72 11 11 60 29 
Newborn sequencing 64 36 0 11 72 17 
Maternal-fetal DNA sequencing 29 65 6 11 66 23 
Rare disease diagnosis 23 71 6 6 77 17 
Microbial pathogen identif cation 17 72 11 11 36 53 
RNA prof ling 50 50 0 11 66 23 
Metabolomics 53 47 0 11 78 11 
Proteomics 64 36 0 29 60 11 
Systematic family history 17 36 46 6 23 71 
Genetic counselors 23 47 30 6 17 77 
EMRs 23 47 30 6 0 94 
Clinical-decision support 33 33 33 6 0 94
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Perhaps the largest such ef ort is the UK 
project to sequence 100,000 whole genomes 
by 2017 through the creation of Genomics 
England (table S1) (7).   is project builds 
on a national strategy to link the National 
Health Service (NHS) EMRs to genomic-
medicine research and development (table 
S1), focusing initially on NHS patients with 
cancer and rare and infectious diseases. 
  e sequenced genomes will be analyzed 
to enhance each patient’s clinical care as 
well as to create a research dataset linked to 
EMRs. Genomics England also aims to train 
the wider health care community in using 
the technology and will build secure data 
linkages to the NHS to ensure that the ef-
fort leads to improvements in patient care. 
Pilot studies of 2,000 patients with rare in-
herited diseases will be completed in 2015, 
and pilot studies of 3,000 patients with lung, 
breast, and colon cancer began in late 2014. 
  e main study will involve the sequenc-
ing of 30,000 whole genomes per year in 
these three emphasis areas through 2017 
and should produce a rich infrastructure of 
next-generation genome sequencing cen-
ters, a sample pipeline and biorepository, 
and large-scale data resources for producing 
new diagnostics and therapies.
Belgium is also building a national 
genome-sequencing pipeline, the Belgian 
medical genomics initiative (BeMGI) (table 
S1)—a comprehensive network of scientists 
and clinicians intended to boost research, 
translate genomics to clinical care, and pre-
pare the next generation of researchers and 
clinicians to use genomic technologies. Cur-
rent ef orts are devoted to collecting and 
sharing variant-frequency data and trans-
lating next-generation genome sequencing 
techniques to clinical practice (for example, 
in diagnosing rare or novel diseases). Simi-
larly, the Estonian government recently ap-
proved a pilot program for personal medi-
cine, which involves the sequencing of 5,000 
Estonian genomes and the development 
of an Estonian-specif c genotyping array, 
coupled with automated decision support 
and training of physicians to use the results 
in everyday practice.   is comprehensive 
approach will be pilot tested in 50,000 indi-
viduals within the Estonian Biobank (8) and 
linked with Estonia’s rich national EMR sys-
tem, through which all residents of Estonia 
can access their personal medical informa-
tion via a smartcard-based national identity 
card. If successful, the resulting array-based 
test will then be of ered to all Estonian resi-
dents ages 35 to 65 years, yielding a database 
of up to 500,000 individuals, each with a lon-
gitudinal EMR, genotype, and prescription 
data for use in disease-risk assessment and 
drug-response prediction as well as in bio-
medical research.
Israel’s Clalit health system has estab-
lished a national laboratory that provides all 
medical institutes in Israel with sequencing-
based panels that assess somatic tissue and 
germline genomic changes for cancer dis-
ease risks and treatment responses. It is also 
testing extensively for founder mutations in 
various disease states and is developing mod-
els of primary care in which patients will be 
routinely tested with broad genomic panels 
by staf  trained to interpret genomic results.
In Australia, newly developing com-
prehensive cancer centers are integrating 
genomics-based cancer research, patient 
care, and education while giving patients 
access to the latest experimental protocols 
and drugs. Several other countries, such as 
Korea and Kuwait, are pursuing more lim-
ited genome-sequencing programs, some in 
close collaboration with the private sector 
to build capacity and expertise.   ese and 
many other participating nations expressed 
their willingness to deposit their resulting 
sequence and phenotype data in widely ac-
cessible databases such as ClinVar (9) or db-
GaP (table S1). Such sharing will not only fa-
cilitate the interpretation of human-genomic 
variation globally but also give external vis-
ibility to these nations’ emerging programs 
and better integrate their scientists into the 
international genomics research community.
Canada’s Genomics and Personalized 
Health competition (GAPH) is a somewhat 
dif erent approach to building national 
genomics capacity and assessing the cost-
ef ectiveness and impact of genomic tech-
nologies on patient outcomes (table S1). 
Seventeen projects have been funded to 
support genomic-medicine implementation 
and related research in health administra-
tion, health technology, and comparative ef-
fectiveness. Close involvement of the private 
sector is an important and innovative com-
ponent and is ref ected in the participation of 
19 biotechnology-oriented companies in the 
project teams. Private-sector involvement is 
also critical to Kuwait’s Genatak sequenc-
ing initiative in which patients themselves 
pay for their whole-genome sequencing 
(table S1). Japan is implementing a program 
somewhat similar to Canada’s GAPH in its 
Implementation of Genomic Medicine 
project to establish a network of genomics-
focused biobanks, build a comprehensive 
genomic-variation database, and perform 
studies to assess clinical ef  cacy and utility 
of genomic information in clinical practice.
A third approach—the use of highly 
focused pilot programs to build capac-
Table 2. Genomic medicine: Barriers to implementation. 
Lack of evidence of the ef ectiveness of genomic interventions and related codependent technolo-
gies* as well as expertise and training programs in genetics, genomics, informatics, and statistics 
High cost and lack of reimbursement for tests and codependent technologies 
Need for evidentiary thresholds for genomic testing; quality-control standards for genome technolo-
gies; and databases with genomic variants linked to clinical phenotypes 
Lack of consensus on what investments are needed in research and health care capacity for ef ective, 
sustainable implementation 
Limited access to educational information and reliable standardized genotyping or sequencing 
platforms 
Lack of bioinformatics and EMR infrastructure to order, receive, act on, and follow up results and as-
sess the impact of clinical interventions 
Concerns over consent and privacy 
Need to align genomic research with the future burden of disease and health needs of patients and 
populations and the development of genomic tests with the development of ef ective co-dependent 
technologies 
Need to consider ethical and legal aspects of the ownership of genomic information and manage 
competing interests in a fair and transparent manner
*A codependent health technology is one that depends on a second technology to achieve or 
enhance the intended ef ect, such as a diagnostic test used to determine a patient subgroup that 
is most likely to respond to a new medication. [www.health.gov.au/internet/hta/publishing.nsf/
Content/co-1]
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Table 3. Opportunities for international collaborations. 
Evidence generation 
• Catalog ongoing evidence-generating projects  
• Assess availability of data and specimens 
• Def ne standards for evidence 
• Establish standards for genetic and genomic tests  
• Encourage development of professional practice guidelines 
• Identify countries/systems willing to enable access to patient data 
• Develop systems to capture outcomes from EMRs and other clinical systems
Health information technology 
• Def ne key elements that should be stored in EMR 
• Identify and share existing IT solutions that are more robust and generalizable (clinical decision support, variant databases, informatics pipelines) 
• Develop global resource for actionable clinical variants 
• Def ne and link necessary federated databases needed to implement genomic medicine 
• Collect and aggregate gene and variant data [for example, Exome Aggregation Consortium (ExAC), ClinVar] 
• Develop controlled vocabulary for phenotypes (ontology); identify available ontologies 
• Establish clearinghouse of genomic medicine implementation guidelines
Education/workforce development 
• Genomics professionals 
○ Collect data on genomic professional workforce and training in dif erent countries 
○ Summarize existing workforce surveys and conduct new ones as needed  
○ Share competencies and training paradigms 
○ Compare training paradigms for geneticists and identify best practices  
○ Examine extending current capabilities by telemedicine and other remote approaches 
• Other health professionals 
○ Examine curricula and determine where genetics competency training can be accommodated 
○ Def ne necessary genomic competencies for trainees at completion of training, which may dif er across regions/countries 
○ Deploy new educational tools, such as distance learning  
○ Develop region/country-specif c teaching materials, perhaps on common templates 
• Public 
○ Adapt existing products and activities, such as DNA Day, to specif c cultures  
○ Extend to students at secondary school level 
○ Engage patient support groups to sponsor programs, develop and distribute educational materials 
○ Provide clearinghouse for accumulated educational resources  
○ Consider novel educational paradigms
Pharmacogenomics 
• Promote improved quality-of-evidence base for pharmacogenomics implementation 
•  Prioritize for study and implementation inexpensive drugs with risk of treatment failure or severe adverse drug reactions likely to be limited to genetically 
def ned subset 
• Develop and pilot large-scale implementation project around successful programs such as global eradication of genetically mediated SJS/TEN 
Policy 
• Data sharing and regulatory issues 
○ Map current activities and issues being addressed 
○ Perform gap analysis 
○ Establish “network of networks” in policy development to share information 
• Costs and benef ts 
○ Identify burdens of disease and points in care pathway where genomic tools would integrate and have the greatest impact on outcomes 
○ Improve capacity for conducting convincing economic, feasibility, and sustainability analyses  
○  Perform economic, feasibility, and sustainability analyses from perspective of dif erent stakeholders, such as payers, delivery systems, national health 
services  
○ Engage payers and payment decision processes 
○ Work in and learn from systems with one or a few centralized payers
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ity and demonstrate ef ectiveness before 
full-scale implementation—capitalizes on 
disproportionate disease burdens or singu-
lar capabilities within a given country. For 
example, Luxembourg’s Centre for systems 
biomedicine is leveraging local expertise 
in neurobiology, pathway analysis, and 
community-driven annotation (10, 11) to 
create an interactive map that charts the 
genetic and molecular underpinnings of 
Parkinson’s disease (12).   is map will be 
integrated with genome sequence data to fa-
cilitate early diagnosis and molecular strati-
f cation of patients. Singapore’s Personalized 
Omic Lattice for Advanced Research and 
Improving Stratif cation (POLARIS) proj-
ect takes advantage of local expertise and 
interest in genomics and ophthalmology 
in launching a pilot ef ort of transforming 
growth factor–β-induced (TGFBI) sequenc-
ing to assess genetic risk for stromal cor-
neal dystrophies (13).  is ef ort will be fol-
lowed by the implementation of a 90-gene 
panel that targets gastrointestinal cancers—
diseases of high burden in Singapore—in 
a systematic ef ort to develop a nationwide 
framework for genetic and genomic testing.
  ailand’s Ministry of Public Health 
and Ramathibodi Hospital are focusing on 
a condition that occurs at unusually high 
frequency locally and was recently shown to 
have strong genetic determinants. Stevens-
Johnson syndrome/toxic epidermal necrol-
ysis (SJS/TEN) is a devastating and of en 
fatal cutaneous reaction to medications that 
is largely mediated by high-risk HLA alleles. 
  ailand has one of the highest rates of SJS/
TEN in the world, mainly attributable to a 
high frequency of these risk alleles and use 
of causative drugs. Ramathibodi hospital 
has launched a “pharmacogenetics card” 
that can be carried in a wallet and provides 
a patient’s HLA variant information, which 
predicts the risk of contracting SJS/TEN 
from specif c drugs. Initial cost-ef ectiveness 
studies have been suf  ciently convincing 
that the   ai government has agreed to 
provide the testing as standard of care (14). 
Singapore has come to the same conclusion: 
Asian patients who are being considered for 
carbamazepine treatment are of ered HLA-
B*15:02 screening (15, 16).
  ese three brief y described 
approaches—population-wide genomic se-
quencing and EMR integration, coordinated 
nationwide genomic medicine research pro-
grams, and localized ef orts that focus on 
unusual capabilities or needs—demonstrate 
that no country has a monopoly on the im-
plementation of genomic medicine. Quite 
the contrary, implementation is expanding 
globally in diverse and highly innovative 
ways. Yet here again, as noted in early U.S. 
genomic medicine implementation pro-
grams (2), many of these ef orts are being 
conducted with little interaction or collabo-
ration. Given the rapid growth of the genom-
ics-based biotechnology sector (17) and the 
pressure on university-based researchers to 
commercialize their work (18), some degree 
of competition is to be expected. Still, will-
ingness to share ef ective tools and strategies 
through consortia such as the Electronic 
MEdical Records and GEnomics (eMERGE) 
network (19), the PharmacoGenomics 
KnowledgeBase (PharmGKB), the Imple-
menting GeNomics In pracTicE (IGNITE) 
network, and the GAPH, IRDiRC, and 
GA4GH ef orts described above demon-
strate the possibilities for synergistic global 
interactions (table S1). Indeed, the interna-
tional collaborations GA4GH, IRDiRC, and 
GAPH, which focus predominantly on re-
search, illustrate the potential power of such 
alliances and the readiness of the genomics 
community to form them. Given the critical 
need for clinical-evidence generation and 
evaluation of genomic medicine interven-
tions as well as the value of harnessing infor-
mation from diverse populations to capture 
the immensity of human genomic variation, 
international collaborative projects in clini-
cal implementation are an obvious solution.
MULTINATIONAL TEAMWORK
Several areas in particular could benef t 
substantially from multinational collabora-
tions in genomic-medicine implementation 
(Table 3). Even when taking into account 
cultural dif erences as well as variations in 
public perception, governance structures, 
health care systems, resources, infrastruc-
ture, allele frequencies, and prevalent dis-
eases, there is much to be learned and the 
potential for unnecessary duplication is so 
great that some degree of coordination and 
sharing of results is critical. Systematic map-
ping of ongoing implementation projects 
worldwide and an inventory of available 
evidence and evidence-generation projects 
will help to def ne gaps and reveal how a 
particular group can best interact with ex-
isting ef orts. 
Evidence generation. Studies designed 
to determine the value of genomic medicine 
for patients, clinicians, and health care sys-
tems are among the most expensive of the 
potential international collaborations, and 
considerable work is ongoing, as detailed 
above. Despite dif erences in health care 
delivery systems, research in a variety of 
disciplines has demonstrated the value and 
relevance of data accumulated in diverse 
settings (20, 21). International collabora-
tions have amply shown the speed with 
which multinational consortia can answer 
questions that few countries can tackle on 
their own, as demonstrated for survival af er 
myocardial infarction (22), the global bur-
den of disease (23), and HIV/AIDS (24). As 
many genomic-medicine implementation 
projects are already in progress, a critical 
f rst step is to catalog ongoing evidence-
generating projects and the genomics-based 
interventions that they can be used to evalu-
ate. Such a catalog should include the avail-
ability of these projects’ specimens and data, 
including patient data, for additional re-
search. Registries such as the Australia and 
New Zealand clinical trials registry, the E.U. 
Clinical Trials Register, and ClinicalTrials.
gov (table S1) (25) could conceivably be 
adapted to receive and provide information 
about evidence-generation projects in ge-
nomic medicine.
To f ll gaps in evidence identif ed by sur-
veying the cataloged projects, a key next 
step is to identify countries and health care 
systems willing to enable access to patient 
data, within appropriate constraints of pol-
icy, privacy, and consent. Dif erences across 
systems—including but not limited to lan-
guage—also must be evaluated to f nd those 
most scientif cally advantageous for com-
bined analysis. Systems will then be needed 
to capture relevant outcomes from EMRs 
and other clinical systems and settings as 
well as to analyze and interpret the f ndings. 
Funding for these ef orts is needed, but to 
the degree that studies can be embedded 
in ongoing clinical care, costs of evidence 
generation might be reduced substantially 
(26–28).
Another important step is to def ne 
standards for what constitutes suf  cient 
evidence to implement a genomic medi-
cine intervention, which likely will vary de-
pending on whether a gene, genetic variant, 
or genetic test is under consideration and 
whether it would be used for risk prediction, 
diagnosis, treatment, or an understanding 
of pathogenesis. Also needed are additional 
standards for performance of genetic tests, 
with emphasis on interpretation and clinical 
decision support, and standards for incor-
porating genomic information into EMRs. 
Once a suf  cient body of evidence is avail-
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able, professional organizations and policy-
makers will need to develop professional 
practice guidelines suitable to a specif c set-
ting or country. For example, the National 
Health and Medical Research Councils of 
Australia and New Zealand are developing 
a framework and principles to facilitate the 
translation of genomic-based tests from dis-
covery to health care (table S1).
Health information technology. With 
the possible exception of imaging, few areas 
of medicine are as dependent on informa-
tion technology (IT) as genomics, given 
the vastness of genome sequence data. Al-
though sequence data can and likely should 
be stored and manipulated outside EMRs 
(29), extracting even the clinically relevant 
genomic variants found in a single patient is 
a challenging task. Because of the rapid evo-
lution of knowledge about clinically relevant 
variants and the changing clinical situation 
of an individual patient, a dynamic ap-
proach is needed for presenting variant in-
formation only when it can potentially make 
a dif erence in that individual’s care (30). In 
addition, genome sequence data should ide-
ally be retrievable for use later in a patient’s 
clinical course and throughout their lifetime 
and should be accessible to other specialists 
and care systems as needed.
A critical f rst step is to def ne the key 
data elements that should be stored in the 
EMR, so that construction of IT systems can 
accommodate them. Truly global resources 
for actionable clinical genomic variants are 
urgently needed and could build on cur-
rent ef orts such as the Clinical Genome 
Resource (ClinGen) (table S1) (31), which 
includes the ClinVar database of the U.S. 
National Center for Biotechnology Infor-
mation (9). Other federated databases nec-
essary to interpret variants and implement 
genomic medicine, such as the international 
Exome Aggregation Consortium (ExAC) 
dataset (table S1) and the Sanger Institute’s 
Database of Chromosomal Imbalance and 
PHenotype in humans using Ensembl Re-
sources (DECIPHER) (32), are needed, as 
is the aggregation of worldwide genomic-
variant data and agreed-upon strategies to 
create relevant reference genome sequences 
where needed to underpin these resources. 
Use of available and widely accepted con-
trolled vocabularies (ontologies) for phe-
notypes and avoidance of proliferation of 
local or regional ontologies will be essential 
to the interpretation of variants and sharing 
of information.   e Innovative Medicine 
initiative project ETRIKS, funded jointly by 
the European Union and industry, aims to 
create and run an open, sustainable research 
informatics and analytics platform for shar-
ing data and supporting translational re-
search in personalized medicine (table S1).
Education and workforce develop-
ment. Educational needs will vary by target 
group (Table 3). Assessment of the cur-
rently available genomic professional work-
force and estimates of workforce needs—
although likely to show shortages at almost 
every level in almost every country—will 
help to prioritize educational programs 
that can then be tailored to the settings in 
which genomics-based care will be deliv-
ered, such as through routine primary care, 
specialized genetic clinics, or pharmacists 
or other allied health personnel. Compe-
tencies need to be def ned and appropriate 
educational programs developed for health 
care professionals at multiple levels within 
a given system (see National Coalition for 
Health Professional Education in Genetics, 
table S1) (33). Integration of genomics into 
health-professional curricula is becoming 
increasingly necessary, and, although trans-
lation for language and cultural appropriate-
ness will be needed, global sharing, rather 
than reinventing, of ef ective training para-
digms and best practices is a worthwhile en-
deavor. Online tools help to facilitate rapid 
implementation and global distribution (for 
example, Coursera and EuroGenTest clini-
cal utility gene cards, table S1). Educational 
materials for patients, policy-makers, and 
regulatory agents should also be built from 
new and available resources, translated and 
customized for specif c cultures and target 
audiences, (34), and dispersed through an 
information clearinghouse.
Pharmacogenomics. Several pharma-
cogenomic applications have already been 
widely implemented in the United States and 
elsewhere (1, 35, 36) and could represent an 
“early win” ripe for transnational sharing of 
best practices and lessons learned. Ef ec-
tive international collaborations have been 
formed to study the genomics of adverse 
drug reactions (37, 38), but actual imple-
mentation ef orts have been more isolated. 
  e Pharmacogenomics for Every Nation 
Initiative (PGENI) is a notable exception, 
promoting integration of pharmacogenom-
ics into public health decision-making by 
using population-specif c allele-frequency 
data for nationally tailored drug selection 
in developing nations (table S1). Also being 
used clinically are guidelines from the Phar-
macogenomics research network’s Clinical 
Pharmacogenetics Implementation Con-
sortium (CPIC) (table S1), which provides 
recommendations on drug selection and 
dosing on the basis of an individual’s geno-
typic data.
Collaborative implementation ef orts 
in pharmacogenomics could promote the 
generation of an improved evidence base 
that focuses on inexpensive drugs charac-
terized by treatment failure, such as clopi-
dogrel (39), or severe adverse reactions, 
such as abacavir (40), likely to be limited to 
a genetically def ned subset of patients.  e 
pharmacogenomics card for avoidance of 
SJS/TEN being implemented in  ailand is 
an elegantly simple and practical approach 
for reducing the incidence of one of the 
most feared adverse drug reactions. Wider 
implementation of this approach in neigh-
boring countries that have similar health 
systems and ancestries, with an ultimate aim 
of global eradication of genetically related 
SJS/TEN, appears to be an achievable goal 
around which an international genomic-
medicine collaborative could coalesce.
Application of whole-genome sequenc-
ing in pharmacogenomics eventually could 
fully def ne an individual’s personalized 
pharmacogenomics prof le (41). Customiz-
ing such an approach in a targeted sequenc-
ing ef ort of the several hundred pharma-
cogenes involved in drug metabolism and 
transport or a smaller subset of clinically 
actionable pharmacogenes would reduce 
costs and make this application more imme-
diately af ordable than more comprehensive 
sequencing ef orts (42).
Policy and regulatory issues. Multiple 
international initiatives are addressing 
policy needs to facilitate data sharing in ge-
nomic research, particularly the Canadian-
led Public Population Project in genomics 
and Society (P3G) (43) and Global Alliance 
for Genomics and Health (GA4GH) (table 
S1) (14). Such ef orts are quite relevant to 
genomic-medicine implementation and, as 
with the evidence realm, an assessment of 
current activities along with a gap analysis 
are important initial steps. Harmonizing 
national ethical guidelines and regulatory 
frameworks as feasible is essential for suc-
cessful international collaborations, as is 
a complete understanding of regional laws 
that govern genomics research, privacy, and 
conf dentiality. To evaluate costs, risks, and 
benef ts of genomic interventions, one must 
identify diseases for which genomic tools 
would have the greatest impact on patient 
and population outcomes—such as cancers, 
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metabolic disorders, anti-HIV therapy, or 
well-def ned genetic disorders such as cys-
tic f brosis. By integrating economic assess-
ments into translational research, scientists 
and clinicians can determine the utility and 
relative value of genomic interventions and 
use the data to inform clinical decision–
makers and policy-makers. Expanding 
single-country studies of cost-ef ectiveness 
to multiple health care systems, through 
multinational collaborations, may help to 
identify key structural components that 
promote favorable cost-benef t ratios (44).
COMING TOGETHER
  e wealth of international programs ac-
tively engaged in genomic-medicine imple-
mentation and the potential for synergy and 
collaboration among them present exciting 
opportunities for speeding knowledge gen-
eration and improving patient care. Espe-
cially in this online age, none of these proj-
ects should have to labor in isolation. Several 
organizations are already showing the power 
of the international genomics community 
to form ef ective collaborations around 
research, although most are closer to the 
generation of new knowledge than to imple-
mentation of that knowledge for improving 
patient care. Engaging and building on the 
ongoing work of these groups will be criti-
cal in furthering the ef ort without wasteful 
duplication. Coalescing these groups around 
concrete but compelling signature projects 
may have a galvanizing ef ect that will facili-
tate similar programs in the future.
To explore these possibilities, several 
participating investigators and countries 
have formed a Global Genomic Medi-
cine Collaborative (G2MC; www.iom.edu/
G2MC) hosted by the U.S. National Acad-
emy of Medicine as part of its Roundtable 
on Translating Genomic-Based Research for 
Health (table S1). Goals of the G2MC are to 
serve as a nexus for genomic medicine ac-
tivities globally, develop opportunities for 
global genomic-medicine implementation 
and outcomes research, and capture and 
disseminate best practices across the global 
community.
Recognizing that this initial survey 
has likely failed to capture many relevant 
projects and interested countries, the au-
thors invite scientists and policy-makers 
who represent their governments’ genomic 
medicine–implementation ef orts to join 
this collaborative by making their interests 
known to the authors (in particular, G.S.G., 
G.P.P., and J.E.L.W.). Genomic medicine has 
the potential to dramatically change the way 
medical professionals deliver health care. As 
we work toward realizing our common in-
terests in the appropriate implementation of 
genomic medicine, it is indeed encouraging 
to know that none of us need to tackle these 
challenges alone. 
SUPPLEMENTARY MATERIALS
www.sciencetranslationalmedicine.org/cgi/content/
full/7/290/290ps13/DC1 
Table S1. Genomics programs worldwide: URLs 
Table S2. Specialized genomic medicine–implementation 
projects in participating countries and regions
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